The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Five-year follow-up analysis of KarMMa
Larry Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, provides insight into the five-year follow-up analysis of the KarMMa trial (NCT03361748), which evaluated the use of idecabtagene vicleucel (ide-cel) in relapsed/refractory (R/R) multiple myeloma (MM). The analysis of 137 patients showed a 76.6% overall response rate (ORR), a complete response (CR) rate of 34%, and a median progression-free survival (PFS) of 10.8 months, with an improved overall survival (OS) of 28.3 months. Notably, 17% of patients who achieved a CR or better were still in remission at the five-year follow-up. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
